Spironolactone
Product Images NDC 67296-1100

4 FDA label images from Redpharm Drug, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 67296-1100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spironolactone Label (Sdistributi19050808390 0001)

Spironolactone Label (Sdistributi19050808390 0001)
Label for Spironolactone 25 mg tablets, containing 30 tablets per bottle. The label includes NDC 67296-1100-3 and is marked Rx Only. Manufacturer is Amneal Pharmaceuticals Co. (I) Pvt. Ltd., Ahmedabad, India. Distributed by RedPharm Drug, Eden Prairie, MN. The label also shows lot number 81196AX1 and expiration date 07/20.*
FDA Label Image

20 (Spironolactone Tablets Usp 1)

20 (Spironolactone Tablets Usp 1)
Chemical structure of Spironolactone, depicting its molecular arrangement with multiple rings, a lactone ring, and functional groups including acetyl and thioester groups visible in the diagram.*
FDA Label Image

10 (Spironolactone Tablets Usp 2)

10 (Spironolactone Tablets Usp 2)
A Kaplan-Meier survival curve comparing the probability over time (months) between Spironolactone and placebo groups. The graph shows two curves with Spironolactone represented by a dashed line and placebo by a solid line. The y-axis represents probability, and the x-axis represents time in months, illustrating differences in survival or event occurrence over approximately 48 months.*
FDA Label Image

10 (Spironolactone Tablets Usp 3)

10 (Spironolactone Tablets Usp 3)
A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups analyzing Spironolactone versus placebo. Subgroups include age, sex, race, LVEF percentage, heart failure status, NYHA classification, diabetes, serum creatinine, creatinine clearance, potassium levels, digoxin, ACEI, and beta blocker use. Each subgroup's HR with confidence intervals is plotted horizontally with sample sizes indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.